Nintedanib esylate (also known as Nintedanib Ethanesulfonate Salt, BIBF1120 esylate) is the ethanesulfonate salt form of BIBF1120 (Nintedanib), which is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet derived growth factor receptor (PDGFR).
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma.
A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC).
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.
Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients.
Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
Nintedanib in the treatment of idiopathic pulmonary fibrosis.
Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties.
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials.
Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.
 F.Hillberg, et al, Cancer Res., 2008, 68(12), pp 4774-4782.
 M.Kropff, et al, Anticancer Res., 2009, 29(10), pp 4233-4238.
 J.A.Ledermann, et al, J. Clin. Oncol., 2009, 27(15s), pp 5501-5501.
 A.du Bois, et al, Ann. Oncol., 2010, 21(2), pp 370-375.
 K.Mross, et al, Clin. Cancer Res., 2010, 16(1), pp 311-319.
 P.M.Ellis, et al, Clin. Cancer Res., 2010, 16(10), pp 2881-2889.
 I.A.Dimitroulis, et al, Respir. Care., 2014, 59(9), pp 1450-1455.
 N.Ahluwalia, et al, Am. J. Respir. Crit. Care Med., 2014, 190(8), pp 867-878.
 S.Popat, et al, Future Oncol., 2015, 11(3), pp 409-420.